Digital healthcare company Cleerly has wrapped up an oversubscribed Series C funding round totaling $192 million, bringing the New York-based company’s lifetime investment cache to a whopping $248 million. Cleerly is clearly on the rise in the medical technology industry, boasting an innovative AI-based approach for gaining insight from coronary computed tomography (CT) angiograms that provides physicians with additional tools for identification, characterization, and quantification of atherosclerosis (plaque) build-up on the walls of the heart arteries.
The leaders of the lucrative round were Fidelity Management and Research Company as well as funds and accounts advised by T. Rowe Price Associates and T. Rowe Price Investment Management. Additional participants included Novartis, Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, and Breyer Capital; existing investors contributing to this Series C included Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, and DigiTx Partners.
“At Cleerly, we are passionate about our mission to create a new standard of care for heart disease,” said the company’s Founder and Chief Executive Officer, Dr. James Min. “We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care. The status quo for heart health simply isn’t good enough—for patients, providers, or payors—and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now.”
The new money will be used to help expand the Cleerly team, support a more-ambitious commercialization campaign for the company’s products, and proliferate said products for easier patient and physician access to advanced software solutions for disease prevention.
